Basis: FMP quote price / unrounded diluted EPS from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/E ratio is N/A as of 2026-10-06T12:55:58.888Z.
Calculation as of: 2026-10-06T12:55:58.888Z.
Quote observation: 2026-10-05T20:00:01.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 396f74b358d2be52688229160785b883c1ccba5e7e57b4b59ce0869c705c56f9
PE RATIO
N/A
Market Cap
$416.68M
PE Ratio
N/A
TTM Avg
20.42
3Y Avg
20.42
5Y Avg
20.42
Market Cap
$410.54M
PE Ratio
N/A
TTM Avg
22.42
3Y Avg
51.74
5Y Avg
51.74
Market Cap
$408.21M
PE Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$447.43M
PE Ratio
N/A
TTM Avg
139.84
3Y Avg
139.84
5Y Avg
139.84
Market Cap
$450.64M
PE Ratio
41.35
TTM Avg
54.06
3Y Avg
54.06
5Y Avg
54.06
| NAME | MARKET CAP | PE RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Carlsmed, Inc. (CARL) | $415.93M | N/A | N/A | N/A | N/A |
| Arcturus Therapeutics Holdings Inc. (ARCT)vs › | $416.68M | N/A | 20.42 | 20.42 | 20.42 |
| Atea Pharmaceuticals, Inc. (AVIR)vs › | $410.54M | N/A | 22.42 | 51.74 | 51.74 |
| Eikon Therapeutics, Inc. Common Stock (EIKN)vs › | $408.21M | N/A | N/A | N/A | N/A |
| Shoulder Innovations, Inc. (SI)vs › | $406.47M | N/A | N/A | N/A | N/A |
| Editas Medicine, Inc. (EDIT)vs › | $428.16M | N/A | N/A | N/A | N/A |
| Capricor Therapeutics, Inc. (CAPR)vs › | $447.43M | N/A | 139.84 | 139.84 | 139.84 |
| Assembly Biosciences, Inc. (ASMB)vs › | $450.64M | 41.35 | 54.06 | 54.06 | 54.06 |
| DiaMedica Therapeutics Inc. (DMAC)vs › | $453.70M | N/A | N/A | N/A | N/A |
| Canopy Growth Corporation (CGC)vs › | $373.40M | N/A | 4952.81 | 4952.81 | 4952.81 |
Trailing P/E
N/A
Forward P/E
N/A
Forward P/E is calculated using analyst consensus EPS estimates for the current or next fiscal year.
Calculation:
Current Price
$15.30
Forward EPS (Est.)
$-1.45
Forward P/E
N/A
Source: FMP Analyst Consensus Estimates. Forward EPS represents the average analyst estimate for the nearest fiscal year.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
